Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2006-11-30
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ineffective analgesic management of patients with sickle cell disease remains a major problem in the management of the disorder in both adults and children. The pharmacological treatment of acute and chronic pain conditions resulting from vaso-occlusive crises in children with sickle cell disease typically involves the use of opioids. In the outpatient setting, this is most commonly achieved with administration of codeine and/or tramadol, both substrates of cytochrome P450 2D6 (CYP2D6). Currently these drugs are used in this patient population without any information concerning the patient's capacity to metabolize these CYP2D6 substrates which may lead to over and under treatment of pain depending on their CYP2D6 activity. The proposed objectives in this application will address this issue by the development of a pharmacodynamic assessment tool that will objectively assess the response to morphine in terms of analgesic response (pharmacodynamic assessment). This new tool might also serve as a non-invasive technique for CYP2D6 phenotyping if CYP2D6 substrates are used for pain therapy by assessing specifically morphine response. Development of this novel assessment tool will result in improved opioid analgesic therapy in this population. Future anticipated studies will examine the application of this technique in the determination of opioid tolerance and hyperalgesia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CYP2D6-
This arm consists of subjects that are poor metabolizers (PM) and intermediate metabolizers (IM).
Dextromethorphan
one time dose - 0.3mg/kg PO
Codeine
one time dose - 2mg/kg PO
Morphine
one time dose - 0.15mg/kg IV
CYP2D6+
Extensive metabolizers (EM) of codeine
Dextromethorphan
one time dose - 0.3mg/kg PO
Codeine
one time dose - 2mg/kg PO
Morphine
one time dose - 0.15mg/kg IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dextromethorphan
one time dose - 0.3mg/kg PO
Codeine
one time dose - 2mg/kg PO
Morphine
one time dose - 0.15mg/kg IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject is of African American descent
* The subject has sickle cell disease (HbSS)
* The subject has a history of vaso-occlusive crisis occurring within the 6 months prior to enrollment requiring opioid analgesia use
* The subject is willing to remain at the research site for the duration of each study session.
* The subject's parent / legal guardian has provided written informed consent to study participation
* The subject has provided written assent to study participation
Exclusion Criteria
* The subject has a history of smoking
* The subject has a history of alcohol use within the last 24 hours prior to testing session(s)
* The subject has a medical history of neuropathic pain, gastrointestinal, hepatic or renal disease
* The subject has a history of medication use including herbal therapies that are known to inhibit or induce CYP2D6 or morphine
* The subject has known or suspected hypersensitivities / allergies to codeine, morphine or dextromethorphan
* The subject is in active, vaso-occlusive crisis
7 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's National Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julia Finkel
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julia C. Finkel, M.D.
Role: PRINCIPAL_INVESTIGATOR
Children's National Medical Center-PPRU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's National Medical Center
Washington D.C., District of Columbia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3919
Identifier Type: -
Identifier Source: org_study_id